Bayer sounds retreat from a $670 million CAR-T pact in the wake of a patient death
Two months after Atara Biotherapeutics hit the hold button on its lead CAR-T 2.0 therapy following a patient death, putting the company under the watchful eye of the FDA, its Big Pharma partners at Bayer are bowing out of a $670 million global alliance. And the move is forcing a revamp of Atara’s pipeline plans, even as research execs vow to continue work on the two drugs allied with Bayer 18 months ago, which delivered a $60 million cash upfront.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.